Sera Prognostics, Inc. (SERA)

Market Cap	296.52M
Revenue (ttm)	94,000
Net Income (ttm)	-32.24M
Shares Out	33.77M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,205
Open	8.07
Previous Close	8.13
Day's Range	8.07 - 8.85
52-Week Range	4.90 - 12.36
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About SERA

Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: SERA
• Website: https://seraprognostics.com

Financial Performance

In 2023, Sera Prognostics's revenue was $306,000, an increase of 14.18% compared to the previous year's $268,000. Losses were -$36.24 million, -17.98% less than in 2022.